Selective USP7 Inhibition Synergizes with MEK1/2 Inhibitor to Enhance Immune Responses and Potentiate Anti–PD-1 Therapy in NRAS-Mutant Melanoma

Liya Su(Southern Illinois University School of Medicine), Weijia Cai(Thomas Jefferson University)
Journal of Investigative Dermatology
April 9, 2025
10.1016/j.jid.2025.03.021
Cited by 9

Related Papers

PBRM1 acts as a p53 lysine-acetylation reader to suppress renal tumor growth
|Nature Communications|2019|79
Loss of 4E-BP1 function induces EMT and promotes cancer cell migration and invasion via cap-dependent translational activation of snail
|Oncotarget|2014|56
A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in <i>NRAS</i> Mutant Melanoma
|Cancer Research|2022|25